Market Cap
Novo Nordisk A/S
kr.4.320 Trillion
DKK as of July 1, 2024
US$622.07 Billion
Company | Market Cap (USD) |
---|---|
Vertex Pharmaceuticals Incorporated | $121.36 B |
Regeneron Pharmaceuticals, Inc. | $115.11 B |
CSL Limited | $95.75 B |
Marinomed Biotech AG | $75.67 B |
Moderna, Inc. | $44.44 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
AbbVie | $295.34 B |
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Novo Nordisk is a global healthcare company involved in the research, development, manufacture, and marketing of pharmaceutical products. It operates through two segments: Diabetes and Obesity care, providing products for insulins, GLP-1, oral antidiabetic products, obesity, and other chronic diseases; and Biopharm, offering products for haemophilia, growth disorders, and hormone replacement therapy.
Novo Nordisk A/S has the following listings and related stock indices.
Stock: OMXC: NOVO.B
Stock: FSX: NOVC
Stock: XETR: NOVC
Stock: XETR: NOVA
Stock: FSX: NOVA
Stock: BMV: NVON
Stock: NYSE: NVO
Stock: Bovespa: N1VO34
The market capitalization of a company, more simply referred to as "market cap", is the total market value of a publicly traded company's outstanding shares. It is often considered as a key indicator of what a company is worth.